Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

Wed, 31st Jan 2024 08:55

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

The FTSE 100 index opened up 2.76 points at 7,669.07. The FTSE 250 was down 11.48 points at 19,338.02, and the AIM All-Share was down 0.19 of a points at 754.70.

The Cboe UK 100 was down 0.1% at 765.96, the Cboe UK 250 was down 0.1% at 16,798.28, and the Cboe Small Companies was down 0.1% at 14,733.78.

In the US on Tuesday, Wall Street ended mixed, as investors looked ahead to Wednesday's interest rate decision. The Dow Jones Industrial Average was up 0.4%, whilst the S&P 500 was down 0.1% and the Nasdaq Composite was down 0.8%.

On Wednesday, all eyes will be on the latest interest rate decision from the US. The Fed will announce its latest decision at 1900 GMT.

It is expected to leave the federal funds rate range unmoved at 5.25% to 5.50%. What happens next has markets divided, however.

According to the CME FedWatch Tool, there is a 45% chance the central bank cuts rates in the following meeting in March. That probability stood at 73% a month ago.

Focus on Wednesday will be on whether the Fed Chair Jerome Powell offers any clues on the interest rate outlook.

Eyes will then swiftly turn onto the Bank of England, which will announce its latest interest rate decision at 1200 GMT on Thursday. Like the Fed, the BoE is expected to keep rates unchanged.

In early economic news, UK house prices edged higher in January, according to Nationwide.

The Nationwide house price index showed a 0.7% increase in seasonally-adjusted UK house prices in January, after showing no change in December. According to FXStreet, market consensus expected the house price index to edge up 0.1% on-month.

In January, the average UK house price stood at GBP257,656, up slightly from GBP257,443 in December, without seasonal adjustment.

Annually, the house price index edged down 0.2%, slowing from a 1.8% decline in December. This came in lower than consensus, with markets pencilling in a 0.9% fell.

"There have been some encouraging signs for potential buyers recently with mortgage rates continuing to trend down. This follows a shift in view amongst investors around the future path of Bank Rate, with investors becoming more optimistic that the Bank of England will lower rates in the years ahead," said Robert Gardner, Nationwide's chief economist.

On the back of the data, housebuilders were trading higher. Taylor Wimpey jumped 1.0%, Barratt Developments rose 0.4% and Persimmon edged up 0.3%.

Elsewhere in the FTSE 100, GSK fell 0.4% as it announced a lower total dividend for 2023.

GSK reported that turnover in 2023 rose 3.4% to GBP30.33 billion from GBP29.32 billion a year earlier.

Notably, GSK reported GBP1.24 billion in revenue for its respiratory syncytial virus vaccine Arexvy, which received approval in the US, the EU, Japan, the UK and Canada in 2023.

Pretax profit in the year climbed 7.7% to GBP6.06 billion from GBP5.63 billion.

On the back of the results, the pharmaceutical company paid out a dividend of 16p, bringing the full year dividend to 58p, which was 5.3% lower than a total payout of 61.25p in 2022.

Looking ahead, GSK said it expects turnover growth between 5% and 7% in 2024. It expects to pay a dividend of 60p per share.

Chief Executive Emma Walmsley said: "GSK delivered excellent performance in 2023, with clear highlights being the exceptional launch of Arexvy and continued progress in our pipeline. We are now planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory and oncology."

In the FTSE 250, Harbour Energy lost 4.5%.

Goldman cut its stock to 'sell' from 'buy'.

Other FTSE 250 stocks were also hurt by stock broker cuts.

Morgan Advanced lost 2.5% and Victrex fell 1.8%. Both companies saw a rating cut by Jefferies.

Meanwhile, FDM lost 1.9% on the back of a trading update.

The IT-focused professional services provider expects its financial performance to be in line with expectations. Revenue for the year is expected to edge up to GBP334 million up from GBP330 million a year earlier.

"The last nine months of 2023 saw difficult trading conditions across our markets, with many clients delaying and deferring decisions around projects and consultant placements given the macro-economic and geo-political uncertainties they faced. Our agile business model allowed us to take the action required to align our business activity and resources appropriately, a programme which continues into the current year," said CEO Rod Flavell.

On AIM, Pebble Beach jumped 30%.

The company said its 2023 trading performance was ahead of market forecasts, with revenue up to GBP12.4 million from GBP11.2 million a year earlier.

he revenue generated by Pebble Beach includes recurring revenue of approximately GBP5.2 million up 13% from GBP4.6 million.

In Asia on Wednesday, the Nikkei 225 index in Tokyo was up 0.6%. In China, the Shanghai Composite was down 1.5%, while the Hang Seng index in Hong Kong was down 1.4%. The S&P/ASX 200 in Sydney closed up 1.1%.

In European equities on Wednesday, the CAC 40 in Paris was up 0.3%, while the DAX 40 in Frankfurt was up 0.1%.

The pound was quoted at USD1.2695 early on Wednesday in London, higher compared to USD1.2665 at the equities close on Tuesday. The euro stood at USD1.0823, down against USD1.0839. Against the yen, the dollar was trading at JPY147.43, down compared to JPY147.80.

Brent oil was quoted at USD82.14 a barrel early in London on Wednesday, down from USD82.32 late Tuesday. Gold was quoted at USD2,040.19 an ounce, higher against USD2,033.15.

Still to come on Wednesday's economic calendar, there is German consumer price inflation data.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.